Brand Institute announced its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022. As a product, VEGZELMA® (bevacizumab-adcd) is the fourth bevacizumab biosimilar currently approved in the United States. VEGZELMA® is indicated for the treatment of patients with: Metastatic colorectal cancer; Recurrent or metastatic non-squamous non-small cell lung cancer; Recurrent glioblastoma; Metastatic renal cell carcinoma; Persistent, recurrent, or metastatic cervical cancer; and Epithelial ovarian, fallopian tube, or primary peritoneal cancer.
1st Jan change | Capi. | |
---|---|---|
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-21.49% | 29.36B | |
+58.56% | 24.49B | |
-14.20% | 17.31B | |
-18.65% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |